📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. (2022)

First Author: Watson-Jones D

Attributed to: A Dose Reduction Immunobridging Study of two HPV vaccines in Tanzanian girls funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2214-109x(22)00309-6

PubMed Identifier: 36113531

Publication URI: http://europepmc.org/abstract/MED/36113531

Type: Journal Article/Review

Volume: 10

Parent Publication: The Lancet. Global health

Issue: 10

ISSN: 2214-109X